SCHEMBL165416

SCHEMBL165416

CCCCCCC(C)(OCC)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CES2 O00748 1/20 0.40
MAPT P10636 1/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GPR84 Q9NQS5 7/20 0.39
PPARG P37231 7/20 0.39
PPARD Q03181 7/20 0.39
PPARA Q07869 7/20 0.39
HDAC11 Q96DB2 5/20 0.39
TSHR P16473 4/20 0.39
PTPN1 P18031 3/20 0.39
ALDH1A1 P00352 2/20 0.39
TLR2 O60603 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
FABP4 P15090 2/20 0.39
SLC22A6 Q4U2R8 1/20 0.39
SLC22A8 Q8TCC7 1/20 0.39
ESR1 P03372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9335557 1.00 MEN1 (0.40) MEN1KMT2ACES2MAPTATM
SCHEMBL3294522 1.00 MEN1 (0.40) MEN1KMT2ACES2MAPTATM
SCHEMBL3285404 0.92 ALDH1A1 (0.35) ATMGPR84TSHRALDH1A1SLC22A6
SCHEMBL689136 0.87 TP53 (0.45) CES2TSHR
SCHEMBL28023365 0.87 TP53 (0.45) CES2TSHR
SCHEMBL28023410 0.87 TP53 (0.45) CES2TSHR
SCHEMBL2477671 0.87 TP53 (0.45) CES2TSHR
SCHEMBL12804020 0.87 TP53 (0.45) CES2TSHR
SCHEMBL3285281 0.84 CES2 (0.42) MEN1KMT2ACES2GPR84PPARG
SCHEMBL3280834 0.84 CES2 (0.42) MEN1KMT2ACES2GPR84PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282807-A1 PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS AMPHISTAR (BE) 2025-09-11 US claimed
EP-3692981-B1 TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF PSORIASIS CHEM CURE ASS LLC (US) 2022-05-04 EP claimed
EP-3305299-B1 METHOD AND COMPOSITIONS FOR TREATING PSORIASIS ANAPLASI PHARMACEUTICALS LLC (US) 2020-04-29 EP claimed
EP-2363112-B1 OSMOTIC DELIVERY SYSTEMS AND PISTON ASSEMBLIES INTARCIA THERAPEUTICS INC (US) 2018-10-10 EP claimed
EP-2906199-B1 METHOD AND COMPOSITIONS FOR TREATING PSORIASIS ANAPLASI PHARMACEUTICALS LLC (US) 2018-01-03 EP claimed
EP-2285212-B1 NOVEL PYRIPROXYFEN COMPOSITIONS SUMITOMO CHEMICAL CO (JP) 2016-02-17 EP claimed
EP-1814652-B1 SURFACTANT SYSTEM METHOD SURFACE ACTIVE SOLUTIONS HOLDINGS LTD (GB) 2015-06-17 EP claimed
EP-0768817-B1 EMULSIFIABLE CONCENTRATES CONTAINING ONE OR MORE PESTICIDES HOECHST SCHERING AGREVO SA (FR) 2000-03-15 EP claimed
US-20250282807-A1 PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS AMPHISTAR (BE) 2025-09-11 US disclosed
EP-4313350-A1 PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS AMPHISTAR BV (BE) 2024-02-07 EP disclosed
WO-2022207086-A1 PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS BIO BASE EUROPE PILOT PLANT VZW (BE) 2022-10-06 WO disclosed
EP-3300795-B1 A PROCESS FOR OBTAINING MICROCAPSULES SIPCAM OXON S P A (IT) 2021-06-30 EP disclosed
US-20200102255-A1 NEW METHOD FOR FERTILIZING AGRICULTURAL SOIL BASF CORPORATION 2020-04-02 US disclosed
EP-2718411-B1 SOPHOROLACTONE COMPOSITIONS AND USES THEREOF ECOVER CO ORDINATION CENTER N V (BE) 2019-09-11 EP disclosed
EP-2378867-A2 AGROCHEMICAL FORMULATIONS CONTAINING PYRROLIDONE ALKYLENE OXIDES BASF SE (DE) 2011-10-26 EP disclosed
WO-2011029561-A2 PESTICIDE PREPARATIONS CLARIANT INTERNATIONAL LTD (CH) 2011-03-17 WO disclosed
WO-2011012493-A2 PESTICIDAL SUSPO-EMULSION COMPOSITIONS BASF SE (DE) 2011-02-03 WO disclosed
WO-2010069848-A2 AGROCHEMICAL FORMULATIONS CONTAINING PYRROLIDONE ALKYLENE OXIDES BASF SE (DE) 2010-06-24 WO disclosed
EP-2152843-A2 MIXTURE COMPRISING AN ALKYL POLYGLUCOSIDE, A COSURFACTANT AND A POLYMER ADDITIVE Bernd Schwegmann Gmbh&co. Kg (DE) 2010-02-17 EP disclosed
WO-2008132202-A2 MIXTURE COMPRISING AN ALKYL POLYGLUCOSIDE, A COSURFACTANT AND A POLYMER ADDITIVE BERND SCHWEGMANN GMBH & CO. KG (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282807-A1 PROCESS FOR ISOLATION AND/OR PURIFYING OF GLYCOLIPIDS MGLL, LIPA, LIPC MEN1 3783/4885KMT2A 2733/4885CES2 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.